Marta Tesone
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Marta Tesone has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Fernanda Parborell
Instituto de Biología y Medicina Experimental (IByME) - CONICET, Buenos Aires, Argentina
5 shared publicationsDalhia Abramovich
Consejo Nacl Invest Cient & Tecn, Inst Biol & Med Expt, RA-1033 Buenos Aires, DF, Argentina
4 shared publicationsGriselda Irusta
Consejo Nacl Invest Cient & Tecn, Inst Biol & Med Expt, RA-1033 Buenos Aires, DF, Argentina
4 shared publicationsDiana Bas
Instituto de Biología y Medicina Experimental-CONICET, Universidad de Buenos Aires, Buenos Aires, Argentina
2 shared publicationsFatima Hernandez
Instituto de Biologa y Medicina Experimental IBYMECONICET, Universidad de Buenos Aires, Buenos Aires, Argentina
2 shared publicationsAlejandra Rodríguez Celín
Instituto de Biología y Medicina Experimental (IBYME)‐CONICET, Departamento de Fisiología, Universidad de Buenos Aires, Buenos Aires, Argentina
1 shared publication
Latest Publications
- 1 August 2011
- Published by Elsevier in Molecular and Cellular Endocrinology
- Vol. 343 (1-2) , 79-87
Angiopoietin 1 reduces rat follicular atresia mediated by apoptosis through the PI3K/Akt pathway
- 1 August 2011
- Published by Elsevier in Molecular and Cellular Endocrinology
- Vol. 343 (1-2) , 79-87
Angiopoietin 1 reduces rat follicular atresia mediated by apoptosis through the PI3K/Akt pathway
- Open Access
- 18 March 2011
- Published by Wiley in Cell Biology International
- Vol. 35 (5) , 423-429
Altered expression of Bcl-2 and Bax in follicles within dehydroepiandrosterone-induced polycystic ovaries in rats
PCOS (polycystic ovary syndrome) is a heterogeneous disease characterized by hyperandrogenaemia, hirsutism, oligo- or amenorrhea, insulin resistance and anovulation. The aim of the present study was to evaluate if the balance between the ovarian expression of Bax (proapoptotic protein) and Bcl-2 (antiapoptotic protein) is altered in a PCOS model developed in rats by DHEA (dehydroepiandrosterone) administration. In addition, the ovarian morphology and the circulating progesterone levels were evaluated. Histological studies confirmed the presence of follicular cysts, atretic follicles and the absence of corpora lutea in the ovaries from the PCOS group and a significant decrease in circulating progesterone levels. Immunohistochemical studies showed that the expression of Bcl-2 and Bax were mainly localized in granulosa cells of AFs (antral follicles) in both groups. Bax expression was greater in preantral and AFs from PCOS ovarian sections than in the controls. In contrast, intense Bcl-2 immunostaining was observed in the control AFs, while Bcl-2 protein was either absent in PFs (preantral follicles) or weakly expressed in AFs from PCOS rats. These results were partially confirmed by Western studies. Data revealed that the ovarian level of Bcl-2 protein was lower in PCOS than in the control and that there were no differences in Bax ovarian levels between groups. However, Bax/Bcl-2 ratio was significantly higher in PCOS group than in the control group. In conclusion, an increase in ovarian apoptosis through an imbalance among the Bcl-2 family members may be involved in the transformation of growing follicles in cystic follicles in the ovaries from DHEA-induced PCOS rats.
- 18 March 2011
- Published by Wiley in Cell Biology International
- Vol. 35 (5) , 423-429
Open AccessAltered expression of Bcl-2 and Bax in follicles within dehydroepiandrosterone-induced polycystic ovaries in rats
PCOS (polycystic ovary syndrome) is a heterogeneous disease characterized by hyperandrogenaemia, hirsutism, oligo- or amenorrhea, insulin resistance and anovulation. The aim of the present study was to evaluate if the balance between the ovarian expression of Bax (proapoptotic protein) and Bcl-2 (antiapoptotic protein) is altered in a PCOS model developed in rats by DHEA (dehydroepiandrosterone) administration. In addition, the ovarian morphology and the circulating progesterone levels were evaluated. Histological studies confirmed the presence of follicular cysts, atretic follicles and the absence of corpora lutea in the ovaries from the PCOS group and a significant decrease in circulating progesterone levels. Immunohistochemical studies showed that the expression of Bcl-2 and Bax were mainly localized in granulosa cells of AFs (antral follicles) in both groups. Bax expression was greater in preantral and AFs from PCOS ovarian sections than in the controls. In contrast, intense Bcl-2 immunostaining was observed in the control AFs, while Bcl-2 protein was either absent in PFs (preantral follicles) or weakly expressed in AFs from PCOS rats. These results were partially confirmed by Western studies. Data revealed that the ovarian level of Bcl-2 protein was lower in PCOS than in the control and that there were no differences in Bax ovarian levels between groups. However, Bax/Bcl-2 ratio was significantly higher in PCOS group than in the control group. In conclusion, an increase in ovarian apoptosis through an imbalance among the Bcl-2 family members may be involved in the transformation of growing follicles in cystic follicles in the ovaries from DHEA-induced PCOS rats.
- Open Access
- 30 July 2009
- Published by Wiley in Molecular Reproduction and Development
- Vol. 76 (12) , 1153-1164
Local effects of the sphingosine 1‐phosphate on prostaglandin F2alpha‐induced luteolysis in the pregnant rat
Since the regression of the corpus luteum (CL) occurs via a tightly controlled apoptotic process, studies were designed to determine if local administration of the antiapoptotic agent sphingosine 1‐phosphate (S1P) effectively blocks the luteolytic action of prostaglandin F‐2alpha (PGF‐2α). On day 19 of pregnancy, 2 hr before systemic PGF‐2α administration, rats were injected intrabursa with either S1P or vehicle (control). The activity of four caspases, which contribute to the initial (caspase‐2, ‐8, and ‐9) and final (caspase‐3) events in apoptosis was measured in pooled CL from four individual ovaries at 0 and 4 hr after PGF‐2α injection. The expression of the phosphorylated form of AKT (pAKT) and tumor necrosis factor‐alpha (TNF‐α) was analyzed by ELISA. In addition, cell death was evaluated by electronic microscopy (EM) in CL 4 and 36 hr after PGF‐2α injection. The activity of caspase‐2, ‐3, and ‐8 was significantly greater by 4 hr after PGF‐2α, but not caspase‐9 activity. In contrast, expression of pAKT and TNF‐α decreased significantly. Administration of S1P suppressed (P < 0.05) these effects, decreasing caspase activities and increasing pAKT and TNF‐α expression. The administration of S1P also significantly decreased the percentage of luteal apoptotic cells induced by PGF‐2α. PGF‐2α treatment increased the prevalence of luteal cells with advanced signs of apoptosis (i.e., multiple nuclear fragments, chromatin condensation, or apoptotic bodies). S1P treatment suppressed these changes and increased the blood vessel density. These results suggest that S1P blocks the luteolytic effect of the PGF‐2α by decreasing caspase‐2, ‐3, and ‐8 activities and increasing AKT phosphorylation and TNF‐α expression. Mol. Reprod. Dev. 76: 1153–1164, 2009.
- 30 July 2009
- Published by Wiley in Molecular Reproduction and Development
- Vol. 76 (12) , 1153-1164
Open AccessLocal effects of the sphingosine 1‐phosphate on prostaglandin F2alpha‐induced luteolysis in the pregnant rat
Since the regression of the corpus luteum (CL) occurs via a tightly controlled apoptotic process, studies were designed to determine if local administration of the antiapoptotic agent sphingosine 1‐phosphate (S1P) effectively blocks the luteolytic action of prostaglandin F‐2alpha (PGF‐2α). On day 19 of pregnancy, 2 hr before systemic PGF‐2α administration, rats were injected intrabursa with either S1P or vehicle (control). The activity of four caspases, which contribute to the initial (caspase‐2, ‐8, and ‐9) and final (caspase‐3) events in apoptosis was measured in pooled CL from four individual ovaries at 0 and 4 hr after PGF‐2α injection. The expression of the phosphorylated form of AKT (pAKT) and tumor necrosis factor‐alpha (TNF‐α) was analyzed by ELISA. In addition, cell death was evaluated by electronic microscopy (EM) in CL 4 and 36 hr after PGF‐2α injection. The activity of caspase‐2, ‐3, and ‐8 was significantly greater by 4 hr after PGF‐2α, but not caspase‐9 activity. In contrast, expression of pAKT and TNF‐α decreased significantly. Administration of S1P suppressed (P < 0.05) these effects, decreasing caspase activities and increasing pAKT and TNF‐α expression. The administration of S1P also significantly decreased the percentage of luteal apoptotic cells induced by PGF‐2α. PGF‐2α treatment increased the prevalence of luteal cells with advanced signs of apoptosis (i.e., multiple nuclear fragments, chromatin condensation, or apoptotic bodies). S1P treatment suppressed these changes and increased the blood vessel density. These results suggest that S1P blocks the luteolytic effect of the PGF‐2α by decreasing caspase‐2, ‐3, and ‐8 activities and increasing AKT phosphorylation and TNF‐α expression. Mol. Reprod. Dev. 76: 1153–1164, 2009.
- 1 October 2008
- Published by S. Karger AG in Gynecologic and Obstetric Investigation
- Vol. 66 (Suppl. 1) , 10-18
The Role of GnRH Analogues in Endometriosis-Associated Apoptosis and Angiogenesis
It has been postulated that gonadotropin-releasing hormone (GnRH) analogues may act directly on endometrial cells and inhibit their growth and proliferation by regulation of apoptotic and angiogenic mechanisms. Eutopic endometrial cells from patients with endometriosis show an increased proliferation rate and are less susceptible to cell death by apoptosis than those from subjects without the disease. Notably, the GnRH analogue, leuprorelin, inhibits cell proliferation and increases the apoptotic rate in eutopic endometrial cell cultures, an effect that appears to be mediated by an increase in the expression of the pro-apoptotic proteins Bax and FasL and a decrease in the expression of the anti-apoptotic protein Bcl-2. Angiogenesis is an important process in the development of endometrial tissue, and it is regulated by vascular endothelial growth factors (VEGFs) and angiopoietins. VEGF levels are elevated in peritoneal fluid and endometriotic tissue from patients with endometriosis. In addition, it has been demonstrated that the expression of VEGF is potentiated by a variety of cytokines, including IL-1β. Recent studies show that leuprorelin reduces the production of VEGF-A and IL-1β in eutopic endometrial cell cultures, suggesting a mechanism by which it could inhibit the development of endometriosis. Thus, GnRH analogues appear to be effective in reducing the growth of endometrial cells, not only due to their classical pituitary endocrine effects, but also via a direct effect on the endometrial cells themselves.
- 1 October 2008
- Published by S. Karger AG in Gynecologic and Obstetric Investigation
- Vol. 66 (Suppl. 1) , 10-18
The Role of GnRH Analogues in Endometriosis-Associated Apoptosis and Angiogenesis
It has been postulated that gonadotropin-releasing hormone (GnRH) analogues may act directly on endometrial cells and inhibit their growth and proliferation by regulation of apoptotic and angiogenic mechanisms. Eutopic endometrial cells from patients with endometriosis show an increased proliferation rate and are less susceptible to cell death by apoptosis than those from subjects without the disease. Notably, the GnRH analogue, leuprorelin, inhibits cell proliferation and increases the apoptotic rate in eutopic endometrial cell cultures, an effect that appears to be mediated by an increase in the expression of the pro-apoptotic proteins Bax and FasL and a decrease in the expression of the anti-apoptotic protein Bcl-2. Angiogenesis is an important process in the development of endometrial tissue, and it is regulated by vascular endothelial growth factors (VEGFs) and angiopoietins. VEGF levels are elevated in peritoneal fluid and endometriotic tissue from patients with endometriosis. In addition, it has been demonstrated that the expression of VEGF is potentiated by a variety of cytokines, including IL-1β. Recent studies show that leuprorelin reduces the production of VEGF-A and IL-1β in eutopic endometrial cell cultures, suggesting a mechanism by which it could inhibit the development of endometriosis. Thus, GnRH analogues appear to be effective in reducing the growth of endometrial cells, not only due to their classical pituitary endocrine effects, but also via a direct effect on the endometrial cells themselves.
- 1 March 2008
- Published by Oxford University Press (OUP) in Biology of Reproduction
- Vol. 78 (3) , 506-513
Intrabursal Administration of the Antiangiopoietin 1 Antibody Produces a Delay in Rat Follicular Development Associated with an Increase in Ovarian Apoptosis Mediated by Changes in the Expression of BCL2 Related Genes1
The angiopoietin (ANGPT) receptor (TEK) system plays a crucial role in blood vessel development and regression. To date, no reports have addressed the actions of the anti-ANGPT1 antibody on gonadotropin-stimulated follicular development and atresia in the ovary. Therefore, in this study we specifically investigated whether ANGPT1 plays a critical intraovarian survival role for gonadotropin-dependent folliculogenesis. In particular, we examined the effect of local administration of anti-ANGPT1 antibody on follicular development, apoptosis, and expression of BCL2 protein family members (BAX, BCL2, and BCL2L1), TNFRSF6, and FASLG in ovarian follicles from prepubertal eCG-treated rats. The inhibition of ANGPT1 caused an increase in the number of atretic follicles and a decrease in the number of both antral follicles (AFs) and preovulatory follicles in gonadotropin-treated rat ovaries. Taking into account that follicular atresia is mediated by apoptosis, we analyzed the effect of the antibody against ANGPT1 on programmed cell death. The inhibition of the action of ANGPT1 caused an increase both in the number of apoptotic granulosa cells in AFs and in the spontaneous DNA fragmentation of AFs cultured in serum-free medium. Besides, AFs obtained from rats treated with intraovarian antibodies against ANGPT1 showed both a decrease in BCL2 and an increase in BAX protein levels. Moreover, a reduction in the BCL2L1L/BCL2L1S ratio was observed in this group, with a reduction of BCL2L1L greater than that of BCL2L1S, thus showing that the expression of these antiapoptotic proteins is lower in follicles from treated rats than in those from untreated ones. Our findings suggest that the inhibition of ANGPT1 activity causes an increase in the number of atretic follicles mediated by ovarian apoptosis through an imbalance in the ratio of antiapoptotic to proapoptotic proteins. This could take place through a paracrine effect on granulosa cells mediated by the TEK receptor in theca cells. Therefore, these data clearly indicate that ANGPT1 is necessary for follicular development induced by gonadotropins.
- 1 March 2008
- Published by Oxford University Press (OUP) in Biology of Reproduction
- Vol. 78 (3) , 506-513
Intrabursal Administration of the Antiangiopoietin 1 Antibody Produces a Delay in Rat Follicular Development Associated with an Increase in Ovarian Apoptosis Mediated by Changes in the Expression of BCL2 Related Genes1
The angiopoietin (ANGPT) receptor (TEK) system plays a crucial role in blood vessel development and regression. To date, no reports have addressed the actions of the anti-ANGPT1 antibody on gonadotropin-stimulated follicular development and atresia in the ovary. Therefore, in this study we specifically investigated whether ANGPT1 plays a critical intraovarian survival role for gonadotropin-dependent folliculogenesis. In particular, we examined the effect of local administration of anti-ANGPT1 antibody on follicular development, apoptosis, and expression of BCL2 protein family members (BAX, BCL2, and BCL2L1), TNFRSF6, and FASLG in ovarian follicles from prepubertal eCG-treated rats. The inhibition of ANGPT1 caused an increase in the number of atretic follicles and a decrease in the number of both antral follicles (AFs) and preovulatory follicles in gonadotropin-treated rat ovaries. Taking into account that follicular atresia is mediated by apoptosis, we analyzed the effect of the antibody against ANGPT1 on programmed cell death. The inhibition of the action of ANGPT1 caused an increase both in the number of apoptotic granulosa cells in AFs and in the spontaneous DNA fragmentation of AFs cultured in serum-free medium. Besides, AFs obtained from rats treated with intraovarian antibodies against ANGPT1 showed both a decrease in BCL2 and an increase in BAX protein levels. Moreover, a reduction in the BCL2L1L/BCL2L1S ratio was observed in this group, with a reduction of BCL2L1L greater than that of BCL2L1S, thus showing that the expression of these antiapoptotic proteins is lower in follicles from treated rats than in those from untreated ones. Our findings suggest that the inhibition of ANGPT1 activity causes an increase in the number of atretic follicles mediated by ovarian apoptosis through an imbalance in the ratio of antiapoptotic to proapoptotic proteins. This could take place through a paracrine effect on granulosa cells mediated by the TEK receptor in theca cells. Therefore, these data clearly indicate that ANGPT1 is necessary for follicular development induced by gonadotropins.
- 14 September 2007
- Published by Wiley in Molecular Reproduction and Development
- Vol. 75 (4) , 623-631
Regulation of ovarian angiogenesis and apoptosis by GnRH‐I analogs
An adequate vascular supply is important to provide endocrine and paracrine signals during follicular development. We evaluated the direct in vivo effects of both the GnRH‐agonist Leuprolide acetate (LA) and the GnRH‐antagonist Antide (Ant) on the expression of VEGF‐A and ANPT‐1 and their receptors in ovarian follicles from prepubertal eCG‐treated rats. We also examined whether the changes observed in apoptosis by GnRH‐I analogs have an effect on the caspase cascade. LA significantly decreased the levels of VEGF‐A, its receptor Flk‐1, and ANPT‐1 when compared to controls, while the co‐injection of Ant interfered with this effect. No changes were observed in the levels of Tie‐2 after treatment with these analogs. When we measured the follicular content of caspase‐3 protein, we observed that LA significantly increased the level of the active form. The co‐injection of Ant interfered with this effect and Ant alone significantly decreased caspase‐3 cleavage. IHC analyses corroborated these data. Notably, while LA increased caspase‐3 activity levels, Ant decreased them when compared to controls. In follicles obtained from LA‐treated rats, cleavage of PARP (a substrate of caspase‐3) from the intact 113‐kDa protein showed a significant enhancement in an 85‐kDa fragment. The co‐injection of Ant interfered with this effect. Ant alone significantly decreased PARP cleavage as compared to controls. We conclude that the decrease in VEGF‐A, its receptor Flk‐1/KDR, and ANPT‐1 produced by the administration of GnRH‐I agonist is one of the mechanisms involved in ovarian cell apoptosis. This suggests an intraovarian role of an endogenous GnRH‐like peptide in gonadotropin‐induced follicular development. Mol. Reprod. Dev. 75: 623–631, 2008.
- 14 September 2007
- Published by Wiley in Molecular Reproduction and Development
- Vol. 75 (4) , 623-631
Regulation of ovarian angiogenesis and apoptosis by GnRH‐I analogs
An adequate vascular supply is important to provide endocrine and paracrine signals during follicular development. We evaluated the direct in vivo effects of both the GnRH‐agonist Leuprolide acetate (LA) and the GnRH‐antagonist Antide (Ant) on the expression of VEGF‐A and ANPT‐1 and their receptors in ovarian follicles from prepubertal eCG‐treated rats. We also examined whether the changes observed in apoptosis by GnRH‐I analogs have an effect on the caspase cascade. LA significantly decreased the levels of VEGF‐A, its receptor Flk‐1, and ANPT‐1 when compared to controls, while the co‐injection of Ant interfered with this effect. No changes were observed in the levels of Tie‐2 after treatment with these analogs. When we measured the follicular content of caspase‐3 protein, we observed that LA significantly increased the level of the active form. The co‐injection of Ant interfered with this effect and Ant alone significantly decreased caspase‐3 cleavage. IHC analyses corroborated these data. Notably, while LA increased caspase‐3 activity levels, Ant decreased them when compared to controls. In follicles obtained from LA‐treated rats, cleavage of PARP (a substrate of caspase‐3) from the intact 113‐kDa protein showed a significant enhancement in an 85‐kDa fragment. The co‐injection of Ant interfered with this effect. Ant alone significantly decreased PARP cleavage as compared to controls. We conclude that the decrease in VEGF‐A, its receptor Flk‐1/KDR, and ANPT‐1 produced by the administration of GnRH‐I agonist is one of the mechanisms involved in ovarian cell apoptosis. This suggests an intraovarian role of an endogenous GnRH‐like peptide in gonadotropin‐induced follicular development. Mol. Reprod. Dev. 75: 623–631, 2008.
- Open Access
- 1 May 2007
- Published by American Physiological Society in American Journal of Physiology-Endocrinology and Metabolism
- Vol. 292 (5) , E1456-E1464
Inhibition of cytochromeP-450 C17 enzyme by a GnRH agonist in ovarian follicles from gonadotropin-stimulated rats
Our objective was to study the direct action of a GnRH-I agonist, leuprolide acetate (LA), on ovarian steroidogenesis in preovulatory follicles obtained from equine chorionic gonadotropin (eCG)-treated rats. Previously, we have demonstrated an inhibitory effect of LA on steroidogenesis and follicular development. In this study, we tested the hypothesis that gonadotropin-releasing hormone (GnRH) exerts its negative effect on follicular development by inhibiting thecal cytochrome P-450 C17 (P450C17) α-hydroxylase expression and, consequently, androgen synthesis. Studies were carried out in prepubertal female rats injected with either eCG (control) or eCG plus LA (LA) and killed at different time points. Immunohistochemical studies indicated that LA induced steroidogenic acute regulatory protein (StAR) expression mainly in theca cells of preantral and antral follicles. In addition, serum progesterone levels increased significantly (P < 0.05), whereas those of androsterone decreased (P < 0.05) after 8 h of LA treatment. This inhibition caused by LA seemed to be a consequence of the decreased expression of follicular P450C17 α-hydroxylase, as demonstrated by Western blot and RT-PCR techniques. In vitro studies using follicles isolated from 48-h-eCG-treated rats and cultured with LA showed a significant (P < 0.05) inhibition of FSH-induced androsterone follicular content as well as P450C17 α-hydroxylase protein levels, as determined by Western analysis. However, LA increased StAR protein expression in these follicles without significant changes in P450scc enzyme levels. Taking all these findings into account, we suggest that GnRH-I exerts a direct inhibitory action on gonadotropin-induced follicular development by decreasing the temporal expression of the P450C17 enzyme and, consequently, androgen production, thus reducing the supply of estrogens available to developing follicles.
- 1 May 2007
- Published by American Physiological Society in American Journal of Physiology-Endocrinology and Metabolism
- Vol. 292 (5) , E1456-E1464
Open AccessInhibition of cytochromeP-450 C17 enzyme by a GnRH agonist in ovarian follicles from gonadotropin-stimulated rats
Our objective was to study the direct action of a GnRH-I agonist, leuprolide acetate (LA), on ovarian steroidogenesis in preovulatory follicles obtained from equine chorionic gonadotropin (eCG)-treated rats. Previously, we have demonstrated an inhibitory effect of LA on steroidogenesis and follicular development. In this study, we tested the hypothesis that gonadotropin-releasing hormone (GnRH) exerts its negative effect on follicular development by inhibiting thecal cytochrome P-450 C17 (P450C17) α-hydroxylase expression and, consequently, androgen synthesis. Studies were carried out in prepubertal female rats injected with either eCG (control) or eCG plus LA (LA) and killed at different time points. Immunohistochemical studies indicated that LA induced steroidogenic acute regulatory protein (StAR) expression mainly in theca cells of preantral and antral follicles. In addition, serum progesterone levels increased significantly (P < 0.05), whereas those of androsterone decreased (P < 0.05) after 8 h of LA treatment. This inhibition caused by LA seemed to be a consequence of the decreased expression of follicular P450C17 α-hydroxylase, as demonstrated by Western blot and RT-PCR techniques. In vitro studies using follicles isolated from 48-h-eCG-treated rats and cultured with LA showed a significant (P < 0.05) inhibition of FSH-induced androsterone follicular content as well as P450C17 α-hydroxylase protein levels, as determined by Western analysis. However, LA increased StAR protein expression in these follicles without significant changes in P450scc enzyme levels. Taking all these findings into account, we suggest that GnRH-I exerts a direct inhibitory action on gonadotropin-induced follicular development by decreasing the temporal expression of the P450C17 enzyme and, consequently, androgen production, thus reducing the supply of estrogens available to developing follicles.
- 31 August 2001
- Published by Wiley in Molecular Reproduction and Development
- Vol. 60 (2) , 241-247
Gonadotropin‐releasing hormone agonist affects rat ovarian follicle development by interfering with FSH and growth factors on the prevention of apoptosis
Apoptosis is the biological process by which follicular cells are eliminated in atretic follicles. The aim of the present study was to examine the in vitro effect of a GnRH‐a (leuprolide acetate, LA) and its interactions with FSH, dibutyryl cAMP, and growth factors (IGF‐I, EGF, and FGF) on follicular apoptosis in early antral ovarian follicles obtained from prepubertal DES‐ treated rats. Follicles cultured 24 hr in the absence of hormones showed spontaneous onset of apoptotic DNA fragmentation. The presence of FSH suppressed the spontaneous onset of apoptotic DNA fragmentation (75–85%). Quantitative estimation of DNA cleavage from ovarian follicles revealed no significant changes in DNA fragmentation after in vitro LA treatment (1–100 ng/ml). However, coincubation with LA interfered partially with the effects of FSH on apoptosis suppression. This apoptosis suppression was also obtained by treatment with dibutyryl cAMP (80%), and was partially prevented by the presence of LA in the cultures. Follicles were cultured 24 hr with FGF, EGF, or IGF‐I, and these factors suppressed DNA fragmentation (70, 60, and 70% respectively), while the presence of LA (100 ng/ml) in the culture medium prevented this effect. In conclusion, we show that the rescue from apoptotic DNA fragmentation produced in early antral follicles by FSH, cAMP, and growth factors, is prevented by coincubation with LA. This GnRH analog would thus interfere in the pathway of FSH, cAMP and/or growth factors by an as yet unknown mechanism. Mol. Reprod. Dev. 60: 241–247, 2001.
- 31 August 2001
- Published by Wiley in Molecular Reproduction and Development
- Vol. 60 (2) , 241-247
Gonadotropin‐releasing hormone agonist affects rat ovarian follicle development by interfering with FSH and growth factors on the prevention of apoptosis
Apoptosis is the biological process by which follicular cells are eliminated in atretic follicles. The aim of the present study was to examine the in vitro effect of a GnRH‐a (leuprolide acetate, LA) and its interactions with FSH, dibutyryl cAMP, and growth factors (IGF‐I, EGF, and FGF) on follicular apoptosis in early antral ovarian follicles obtained from prepubertal DES‐ treated rats. Follicles cultured 24 hr in the absence of hormones showed spontaneous onset of apoptotic DNA fragmentation. The presence of FSH suppressed the spontaneous onset of apoptotic DNA fragmentation (75–85%). Quantitative estimation of DNA cleavage from ovarian follicles revealed no significant changes in DNA fragmentation after in vitro LA treatment (1–100 ng/ml). However, coincubation with LA interfered partially with the effects of FSH on apoptosis suppression. This apoptosis suppression was also obtained by treatment with dibutyryl cAMP (80%), and was partially prevented by the presence of LA in the cultures. Follicles were cultured 24 hr with FGF, EGF, or IGF‐I, and these factors suppressed DNA fragmentation (70, 60, and 70% respectively), while the presence of LA (100 ng/ml) in the culture medium prevented this effect. In conclusion, we show that the rescue from apoptotic DNA fragmentation produced in early antral follicles by FSH, cAMP, and growth factors, is prevented by coincubation with LA. This GnRH analog would thus interfere in the pathway of FSH, cAMP and/or growth factors by an as yet unknown mechanism. Mol. Reprod. Dev. 60: 241–247, 2001.